Clinical Study
De Novo Donor-Specific HLA Antibody Development and Peripheral Cells in Kidney Transplant Recipients: A Place for Interaction?
Table 1
Patient characteristics.
| | All (%) | DSA negative (%) | DSA positive (%) | |
| Recipient female | 30 (56.6) | 20 (55.6) | 10 (58.8) | 1.000 | Donor female | 30 (56.6) | 21 (58.3) | 9 (52.9) | 0.942 | Recipient age, mean Ā± SD | | | | 0.317 | Donor age, mean Ā± SD | | | | 0.558 | ESRD etiology | | | | | āDiabetes | 6 (11.3) | 4 (11.1) | 2 (11.8) | 0.693 | āLupus | 3 (5.7) | 3 (8.3) | 0 (0) | 0.556 | āGlomerulonephritis | 3 (5.7) | 3 (8.3) | 0 (0) | 0.556 | āHypertension | 2 (3.7) | 2 (5.6) | 0 (0) | 0.827 | āOther | 3 (5.7) | 1 (2.8) | 2 (11.8) | 0.494 | āUnknown | 36 (67.9) | 23 (63.9) | 13 (76.4) | 0.548 | Sensitizing events | | | | | āBlood transfusions | 35 (66.0) | 23 (63.9) | 12 (70.6) | 0.865 | āPregnancies () | 11 (36.7) | 5 (25.0) | 6 (60.0) | 0.108 | Donor type | | | | | āLiving donor | 44 (83) | 29 (80.6) | 15 (88.2) |
0.701 | āDeceased donor | 9 (17) | 7 (19.4) | 2 (11.8) | HLA mismatches | | | | 0.040* | ā0 | 6 (11.3) | 6 (16.7) | 0 (0) | 0.186 | ā1 | 5 (9.5) | 4 (11.1) | 1 (5.9) | 0.917 | ā2 | 6 (11.3) | 5 (13.9) | 1 (5.9) | 0.693 | ā3 | 15 (28.3) | 9 (25) | 6 (35.3) | 0.652 | ā4 | 2 (3.8) | 2 (5.6) | 0 (0) | 0.827 | ā5 | 13 (24.5) | 6 (16.7) | 7 (41.1) | 0.111 | ā6 | 6 (11.3) | 4 (11.1) | 2 (11.8) | 0.693 | Immunosuppression | | | | | āDaclizumab | 42 (79.2) | 26 (72.2) | 16 (94.1) | 0.082 | āCsA+Aza+Pdn | 9 (17.0) | 6 (16.7) | 3 (17.6) | 0.762 | āCsA+MMF+Pdn | 3 (5.7) | 3 (8.3) | 0 (0) | 0.556 | āTac+Aza+Pdn | 18 (34.0) | 13 (36.1) | 5 (29.4) | 0.865 | āTac+MMF+Pdn | 22 (41.5) | 14 (38.9) | 8 (47.1) | 0.791 | āOther | 1 (1.8) | 0 (0) | 1 (5.9) | 0.698 |
|
|
All the patients had a PRA < 10% at transplantation and absence of donor-specific antibodies (DSAs). value by Chi square for trend.
|